Healthcare Industry News: Parkinson’s disease
News Release - March 25, 2010
Proteostasis Therapeutics Announces Additions of Key ExecutivesPeter H. Reinhart Joins as CSO and Gregory P. Licholai is Appointed COO
CAMBRIDGE, Mass.--(HSMN NewsFeed)--Proteostasis Therapeutics announced today the appointments of Peter H. Reinhart, Ph.D., as Chief Scientific Officer and Gregory P. Licholai as Chief Operating Officer. Dr. Reinhart replaces interim CSO, Walter Newman, Ph.D., of Healthcare Ventures, who will remain with the company as a consultant.
“Proteostasis is poised to translate its cutting-edge science into important advancements in discovery medicine. These key additions to our senior management team will provide leadership as we apply our proprietary drug discovery platform to moving novel small molecule therapeutics forward,” said Christopher Mirabelli, Ph.D., Chairman of the Board of Proteostasis. “Peter brings extensive scientific leadership in successfully moving several first-in-class, disease-modifying compounds for neurodegenerative diseases from discovery research into clinical development. Greg’s experience in corporate strategy, corporate and business development and commercial planning will be highly valuable to Proteostasis.”
Dr. Reinhart previously oversaw Neurodegeneration Research at Wyeth Pharmaceuticals (now part of Pfizer), focusing on Alzheimer’s disease, Parkinson’s disease, and stroke programs. During his six-year tenure there, Dr. Reinhart delivered fourteen drug candidates into clinical development. Prior to joining Wyeth, he served as Vice President, Neurodegeneration at Cogent Neuroscience after twelve years as a faculty member at Duke University Medical Center, where he continues to serve as an adjunct professor. Dr. Reinhart is a Scientific Advisor to the Michael J. Fox Foundation for Parkinson’s Research and currently chairs the grant review board. Dr. Reinhart received a B.Sc. and Ph.D. in Biochemistry from Australian National University and did his postdoctoral training in Neurobiology at University Tuebingen, Germany. He has authored more than 90 publications, and serves as a scientific reviewer for Science, Neuron, Nature Drug Discovery, Journal of Neuroscience and Molecular Pharmacology.
Prior to joining Proteostasis, Dr. Licholai was Vice President for Corporate Development and Medical Affairs at Amicus Therapeutics, a company focused on pharmacological chaperones for genetic diseases. Before Amicus, he worked at Domain Associates, a leading healthcare venture capital firm, and as Director of Ventures and Business Development at Medtronic Neurological. Dr. Licholai has an MBA from the Harvard Business School, an M.D. from the Yale University School of Medicine and did his clinical training at the Harvard Medical School affiliates Brigham and Women’s, Children’s and Massachusetts General Hospitals. He was awarded a National Institutes of Health research fellowship in neurological disorders funded by the Howard Hughes Medical Institute. Dr. Licholai is also currently on the board of Immunome, an antibody discovery platform company.
About Proteostasis Therapeutics
Proteostasis Therapeutics is discovering “Proteostasis Regulators” (PRs), small molecule drugs that restore proper protein function to treat neurodegenerative, metabolic, genetic and inflammatory disorders. The Proteostasis Network (PN) is the cellular machinery responsible for protein folding, trafficking and clearance, and it can become imbalanced by the cumulative effects of aging, disease and genetics. PTI was founded by leading scientists who discovered a pioneering approach for treating disease by restoring protein network homeostasis. www.proteostasis.com
Source: Proteostasis Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.